|
Market Closed -
NYSE
04:00:02 2026-10-02 pm EDT
|
5-day change | 1st Jan Change | ||
| 47.03 USD | -0.32% |
|
-4.49% | -4.10% |
| Oct. 02 | Major drugmakers turn to China for licensing deals | RE |
| Oct. 01 | GSK plc : JP Morgan reiterates its Sell rating | ZD |
| Market Cap | 71.3B 94.41B 83.88B 78.23B 135B 9,092B 136B 948B 368B 4,637B 354B 347B 14,908B | P/E 2026 * |
13.8x | P/E 2027 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 92.55B 123B 109B 102B 175B 11,801B 176B 1,230B 477B 6,019B 460B 450B 19,349B | EV / Sales 2026 * |
2.73x | EV / Sales 2027 * | 2.53x |
| Free-Float |
92.75% | Yield 2026 * |
3.91% | Yield 2027 * | 4.21% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Mexican S.E.
| GSK N | End-of-day quote | |
|
Deutsche Boerse AG
| GS70 | Delayed | |
|
Tradegate
| GS70 | Real-time | |
|
Börse Stuttgart
| GS70 | Delayed | |
|
Boerse Muenchen
| GS70 | Real-time |
Last Transcript: GSK plc
| Oct. 01 | GSK plc : JP Morgan reiterates its Sell rating | ZD |
| Sep. 29 | GSK plc : Gets a Neutral rating from Deutsche Bank | ZD |
| Sep. 29 | GSK plc : Jefferies keeps its Buy rating | ZD |
| Sep. 18 | GSK plc : Deutsche Bank remains Neutral | ZD |
| Sep. 17 | GSK plc : UBS is Neutral | ZD |
| 1 day | -0.32% | ||
| 1 week | -4.49% | ||
| Current month | -2.37% | ||
| 1 month | -6.76% | ||
| 3 months | -12.36% | ||
| 6 months | -17.04% | ||
| Current year | -4.10% |
| 1 week | 46.84 |  | 49.82 |
| 1 month | 46.84 | | 51.32 |
| Current year | 46.84 | | 61.7 |
| 1 year | 42.84 | | 61.7 |
| 3 years | 31.72 | | 61.7 |
| 5 years | 28.46 | | 61.7 |
| 10 years | 28.46 | | 61.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.32% | -4.49% | - | - | 94.34B | |
| -0.61% | -3.43% | +39.40% | +112.31% | 1,019B | |
| -1.02% | -5.60% | +37.67% | +65.02% | 617B | |
| +1.11% | -0.58% | +11.10% | +77.28% | 464B | |
| +0.34% | -3.01% | +61.21% | +40.71% | 356B | |
| -0.95% | -4.05% | +21.60% | +39.37% | 333B | |
| -1.46% | -2.89% | +11.84% | +24.60% | 267B | |
| -1.35% | -5.43% | -4.69% | +8.40% | 244B | |
| -1.04% | -2.79% | +35.52% | +51.34% | 218B | |
| -1.87% | -4.10% | +30.92% | +95.33% | 179B | |
| Average | -0.72% | -3.39% | +27.17% | +57.15% | 410.8B | |
| Weighted average by Cap. | -0.59% | -3.33% | +30.52% | +68.96% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.92B 44.91B 39.9B 37.21B 64B 4,325B 64.58B 451B 175B 2,206B 168B 165B 7,092B | 35.5B 47B 41.76B 38.94B 66.98B 4,526B 67.59B 472B 183B 2,309B 176B 173B 7,422B |
| Net income | 5.19B 6.87B 6.11B 5.7B 9.8B 662B 9.88B 69.02B 26.76B 338B 25.78B 25.25B 1,085B | 6.21B 8.22B 7.3B 6.81B 11.72B 792B 11.82B 82.56B 32.01B 404B 30.84B 30.2B 1,298B |
| Net Debt | 21.24B 28.13B 24.99B 23.3B 40.08B 2,709B 40.44B 282B 110B 1,381B 106B 103B 4,441B | 18.52B 24.52B 21.78B 20.31B 34.94B 2,361B 35.26B 246B 95.47B 1,204B 91.97B 90.05B 3,871B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-02 | $47.03 | -0.32% | 5,386,360 |
| 26-10-01 | $47.18 | -2.06% | 7,897,512 |
| 26-09-30 | $48.17 | -2.39% | 5,852,600 |
| 26-09-29 | $49.35 | -0.70% | 2,892,716 |
| 26-09-28 | $49.70 | +0.93% | 3,586,711 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
